Cyclacel Pharma (CYCC) Reports Q2 Loss of $0.10
Tweet
Share
E-mailGet Alerts CYCC Hot Sheet
Price: $6.37 --0%
Financial Fact:
Research and development: 2.41M
Today's EPS Names:
BTTX, VAXX, ELYS, More
Financial Fact:
Research and development: 2.41M
Today's EPS Names:
BTTX, VAXX, ELYS, More
Join SI Premium – FREE
Cyclacel Pharma (NASDAQ: CYCC) reported Q2 EPS of ($0.10), versus ($0.22) reported last year. Revenue for the quarter came in at $356 thousand, versus $296 thousand reported last year.
For earnings history and earnings-related data on Cyclacel Pharma (CYCC) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Walmart (WMT) PT Lowered to $130 at UBS on Investment Narrative's Competing Dynamics
- DA Davidson Reiterates Buy Rating on Box, Inc. (BOX) on Secular Tailwinds for Demand
- Bernstein SocGen on Meta Platforms Inc. (META): 'Risk-reward remains attractive'
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
